Results
85
Biotech stocks worldwide which are expected to become profitable in the next 3 years.
85 companies
Alnylam Pharmaceuticals
Market Cap: US$43.3b
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference.
ALNY
US$331.91
7D
1.8%
1Y
30.1%
CARsgen Therapeutics Holdings
Market Cap: HK$11.9b
An investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China.
2171
HK$21.50
7D
-6.9%
1Y
429.6%
Xbrane Biopharma
Market Cap: SEK 380.3m
A biotechnology company, engages in the development, manufacture, and sale of biosimilars.
XBRANE
SEK 0.25
7D
-3.0%
1Y
12.6%
Ardelyx
Market Cap: US$1.0b
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
ARDX
US$4.27
7D
8.9%
1Y
-21.7%
Akeso
Market Cap: HK$101.4b
A biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide.
9926
HK$113.00
7D
22.9%
1Y
208.3%
Mereo BioPharma Group
Market Cap: US$456.3m
A biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally.
MREO
US$2.87
7D
5.9%
1Y
-21.8%
Innate Pharma
Market Cap: €140.6m
Operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.
IPH
€1.53
7D
0.3%
1Y
-24.1%
Guard Therapeutics International
Market Cap: SEK 350.9m
A pharmaceutical company, identifies, develops, and commercializes therapies for the diagnosis and treatment of acute kidney injuries in Sweden.
GUARD
SEK 17.40
7D
1.2%
1Y
-42.0%
Legend Biotech
Market Cap: US$6.6b
Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
LEGN
US$35.64
7D
0.4%
1Y
-24.8%
Blueprint Medicines
Market Cap: US$8.3b
A precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally.
BPMC
US$128.35
7D
0.1%
1Y
10.3%
Tenaya Therapeutics
Market Cap: US$99.5m
A clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States.
TNYA
US$0.61
7D
0.4%
1Y
-79.0%
Capricor Therapeutics
Market Cap: US$468.5m
A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
CAPR
US$10.25
7D
-8.1%
1Y
113.1%
Vanda Pharmaceuticals
Market Cap: US$292.9m
A biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.
VNDA
US$4.97
7D
5.3%
1Y
-5.7%
Soleno Therapeutics
Market Cap: US$4.4b
A clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
SLNO
US$86.65
7D
3.4%
1Y
104.3%
RenovoRx
Market Cap: US$49.7m
A clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment.
RNXT
US$1.36
7D
6.3%
1Y
19.8%
Abeona Therapeutics
Market Cap: US$301.3m
A clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases.
ABEO
US$5.89
7D
3.7%
1Y
22.7%
Madrigal Pharmaceuticals
Market Cap: US$6.6b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$298.87
7D
-1.2%
1Y
2.8%
Aldeyra Therapeutics
Market Cap: US$257.6m
A biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases.
ALDX
US$4.30
7D
12.3%
1Y
29.9%
ARS Pharmaceuticals
Market Cap: US$1.6b
A biopharmaceutical company, develops and commercializes treatments for severe allergic reactions.
SPRY
US$16.52
7D
-5.3%
1Y
74.3%
Achieve Life Sciences
Market Cap: US$112.2m
A late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom.
ACHV
US$2.18
7D
-3.5%
1Y
-52.4%
OS Therapies
Market Cap: US$54.3m
A clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States.
OSTX
US$1.83
7D
-2.7%
1Y
n/a
Sichuan Kelun-Biotech Biopharmaceutical
Market Cap: HK$80.5b
A biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, and other therapeutic areas in the People’s Republic of China and internationally.
6990
HK$352.40
7D
7.7%
1Y
139.7%
Beijing Luzhu Biotechnology
Market Cap: HK$4.4b
A biotechnology company, focuses on the research and development, production, and sale of human vaccines and therapeutic biologics to prevent and control infectious diseases, and treat cancer and autoimmune diseases in China.
2480
HK$22.05
7D
-8.7%
1Y
-3.3%
Oxford Biomedica
Market Cap: UK£355.0m
A contract development and manufacturing organization, focuses on delivering therapies to patients worldwide.
OXB
UK£3.35
7D
5.7%
1Y
1.1%
Lipigon Pharmaceuticals
Market Cap: SEK 19.0m
Develops drugs for lipid related diseases in Sweden.
LPGO
SEK 0.13
7D
19.1%
1Y
-58.7%
Aelis Farma
Market Cap: €13.2m
A clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France.
AELIS
€0.97
7D
-0.8%
1Y
-92.2%
Precigen
Market Cap: US$478.2m
A discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases.
PGEN
US$1.62
7D
14.1%
1Y
4.5%
Arcutis Biotherapeutics
Market Cap: US$1.6b
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
ARQT
US$13.82
7D
-1.4%
1Y
32.5%
aTyr Pharma
Market Cap: US$472.6m
A clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States.
ATYR
US$5.31
7D
4.7%
1Y
247.1%
Kidswell Bio
Market Cap: JP¥10.0b
Develops pharmaceuticals for the treatment of rare and intractable diseases in Japan.
4584
JP¥227.00
7D
-18.6%
1Y
69.4%
Immutep
Market Cap: AU$365.1m
A late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia.
IMM
AU$0.25
7D
4.2%
1Y
-15.3%
Devyser Diagnostics
Market Cap: SEK 2.2b
Engages in the development, manufacture, and sale of diagnostic kits and solutions for DNA testing within hereditary diseases, oncology, and post-transplantation monitoring in Sweden, rest of Europe, the Middle East, Africa, North and South America, and Asia.
DVYSR
SEK 130.00
7D
2.4%
1Y
17.1%
XOMA Royalty
Market Cap: US$322.6m
Operates as a biotech royalty aggregator in the United States and the Asia Pacific.
XOMA
US$26.96
7D
7.0%
1Y
9.4%
Invivyd
Market Cap: US$88.2m
A biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States.
IVVD
US$0.74
7D
2.8%
1Y
-32.6%
TuHURA Biosciences
Market Cap: US$115.4m
A clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies.
HURA
US$2.48
7D
11.2%
1Y
n/a
ABL Bio
Market Cap: ₩3.0t
A biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases.
A298380
₩61,800.00
7D
-8.0%
1Y
113.1%